D.Western Therapeutics Institute, Inc.
4576・Growth Market・Pharmaceuticals
Governance
Company with an Audit and Supervisory Committee. The Board of Directors consists of 6 members (2 directors who are not Audit and Supervisory Committee members, and 4 directors who are Audit and Supervisory Committee members, of whom 3 are outside directors). All 3 outside directors are designated as independent officers. The annual securities report does not indicate the establishment of a Nomination Committee or Compensation Committee. The Board of Directors met 14 times during the fiscal year under review.
Risk Management
The Company's approach is based on the development of various internal regulations and deliberation by the Board of Directors, with a task force established under the direction of the President and Representative Director in the event of a significant incident. Legal risk is mitigated through an advisory contract with an outside law firm, and a Compliance Committee (chaired by the President and Representative Director, with participation from the retained attorney) has been established, along with an internal whistleblowing hotline for employees. Sustainability-related risks are managed together with other management risks in an integrated manner.
Shareholder Returns
No dividends have been paid since founding. As of the end of the current fiscal year, the Company has no distributable financial resources under the Companies Act. For the time being, the Company prioritizes retaining internal reserves to continue R&D activities, and will consider future dividends while taking into account its financial position and business performance.
Dividend Policy
The Company has not paid dividends since its founding, and as of the end of the current fiscal year, it is not in a financial position to pay dividends under the provisions of the Companies Act. For the time being, the Company will focus on retaining internal reserves and prioritize the continued implementation of R&D activities. If dividends of surplus are to be paid in the future, the Company plans to pay a year-end dividend once per year. The dividend decision-making body is the general meeting of shareholders.
ESG
The company positions social contribution through new drug development as the foundation of its sustainability efforts. In human capital, it works on ensuring diversity, enhancing work-life balance, and improving safety and health environments, having set paid leave utilization rate as a KPI (actual result of 84.7% against a target of 80%). The company employs 19 specialized personnel with an average age of 50.8 years and average tenure of 10.3 years. No quantitative disclosure regarding climate change is provided.
Last updated: March 23, 2026